Compare · ARGX vs WWB
ARGX vs WWB
Side-by-side comparison of argenx SE (ARGX) and Windward Bio Group AG (WWB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and WWB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $58.42B, about 43.3x WWB ($1.35B).
- WWB has been more active in the news (14 items in the past 4 weeks vs 6 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 0 for WWB).
- Company
- argenx SE
- Windward Bio Group AG
- Price
- -
- -
- Market cap
- $58.42B
- $1.35B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2026
- News (4w)
- 6
- 14
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Windward Bio Group AG
Windward Bio Group is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis. Our product candidates, WIN378 and WIN027, target clinically validated disease pathways and are engineered to remain in the body for extended periods of time, enabling less frequent dosing than currently available treatments. This design feature is combined with additional properties including enhanced target affinity, dual target binding or effector function silencing. We believe our product candidates have the potential to deliver better clinical outcomes while offering the convenience of less frequent dosing than currently available treatments.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
- Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
- Amendment: SEC Form SCHEDULE 13G/A filed by argenx SE
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
- argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
- SEC Form 6-K filed by argenx SE
Latest WWB
- Director David P Bonita bought $20,000,007 worth of shares (1,176,471 units at $17.00), converted options into 5,172,944 shares, exercised 216,668 shares at a strike of $0.02 and covered exercise/tax liability with 232 shares (SEC Form 4)
- Director Orbimed Advisors Llc bought $20,000,007 worth of shares (1,176,471 units at $17.00), converted options into 5,172,944 shares, exercised 216,668 shares at a strike of $0.02 and covered exercise/tax liability with 232 shares (SEC Form 4)
- Director Otello Stampacchia bought $29,750,000 worth of shares (1,750,000 units at $17.00) and converted options into 3,588,520 shares (SEC Form 4)
- Windward Bio to Participate at the Jefferies London Global Healthcare Conference
- Director Mufti Iqbal Rasool was granted 22,675 share options (SEC Form 4)
- Chief Operating Officer Harris Kevin Andrew was granted 33,206 shares, increasing direct ownership by 4% to 960,966 units (SEC Form 4)
- Chief Executive Officer Santarelli Luca was granted 815,755 employee share options (SEC Form 4)
- Chief Financial Officer D'Augusta Claudia was granted 180,160 employee share options (SEC Form 4)
- Director Bonita David P was granted 22,675 stock options (SEC Form 4)
- Director Stampacchia Otello was granted 22,675 share options (SEC Form 4)